Shares of Daré Bioscience, Inc. (NASDAQ:DARE – Get Free Report) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.33 and traded as high as $0.37. Daré Bioscience shares last traded at $0.36, with a volume of 270,546 shares changing hands.
Analyst Ratings Changes
Several analysts have issued reports on DARE shares. Dawson James cut Daré Bioscience from a “buy” rating to a “neutral” rating in a report on Tuesday, January 30th. HC Wainwright dropped their price objective on shares of Daré Bioscience from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, November 10th.
Daré Bioscience Stock Performance
Hedge Funds Weigh In On Daré Bioscience
A number of hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new position in Daré Bioscience during the first quarter worth about $34,000. Citigroup Inc. purchased a new position in Daré Bioscience during the first quarter worth about $40,000. BlackRock Inc. boosted its position in shares of Daré Bioscience by 63.7% during the 1st quarter. BlackRock Inc. now owns 602,036 shares of the biotechnology company’s stock worth $897,000 after purchasing an additional 234,243 shares during the period. Vanguard Group Inc. boosted its position in shares of Daré Bioscience by 13.0% during the 1st quarter. Vanguard Group Inc. now owns 3,453,021 shares of the biotechnology company’s stock worth $5,145,000 after purchasing an additional 396,968 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Daré Bioscience during the 1st quarter worth approximately $150,000. 7.41% of the stock is currently owned by hedge funds and other institutional investors.
About Daré Bioscience
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.
- Five stocks we like better than Daré Bioscience
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 attractive stocks that insiders are buying
- Investing in Travel Stocks Benefits
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Which Wall Street Analysts are the Most Accurate?
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.